Search

Roche Holding AG

Затворен

СекторЗдравеопазване

283.2 -0.07

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

282.2

Максимум

284.4

Ключови измерители

By Trading Economics

Приходи

1.7B

3.7B

Продажби

-15B

16B

P/E

Средно за сектора

25.123

37.461

Дивидентна доходност

3.28

Марж на печалбата

23.266

Служители

103,249

EBITDA

547M

6.5B

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

3.28%

2.33%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

22B

227B

Предишно отваряне

283.27

Предишно затваряне

283.2

Настроения в новините

By Acuity

28%

72%

64 / 371 Класиране в Healthcare

Roche Holding AG Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.10.2025 г., 09:32 ч. UTC

Печалби

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue -- Update

23.10.2025 г., 05:54 ч. UTC

Печалби

Roche Raises Full-Year Earnings Outlook

1.10.2025 г., 08:54 ч. UTC

Значими двигатели на пазара

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

18.09.2025 г., 14:01 ч. UTC

Придобивния, сливания и поглъщания

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- 2nd Update

18.09.2025 г., 10:05 ч. UTC

Значими двигатели на пазара
Придобивния, сливания и поглъщания

89bio Shares Soar Premarket on Takeover by Roche

18.09.2025 г., 10:04 ч. UTC

Придобивния, сливания и поглъщания

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- Update

18.09.2025 г., 05:37 ч. UTC

Придобивния, сливания и поглъщания

Roche to Buy 89bio for Up to $3.5 Billion

23.10.2025 г., 09:19 ч. UTC

Пазарно говорене
Печалби

Roche's Sales Slow, But Drug Pipeline Could Support Long-Term Growth -- Market Talk

23.10.2025 г., 09:11 ч. UTC

Пазарно говорене
Печалби

Roche Sales Miss Driven by Underperformance of Key Drugs -- Market Talk

23.10.2025 г., 05:09 ч. UTC

Печалби

Roche 3Q Sales Up 6% At CER

23.10.2025 г., 05:07 ч. UTC

Печалби

Roche 3Q Sales CHF14.92B

23.10.2025 г., 05:07 ч. UTC

Печалби

Analysts Had Seen 3Q Sales At CHF15.17B

23.10.2025 г., 05:07 ч. UTC

Печалби

Roche See Core Earnings Per Share Growth In High-Single to Low-Double-Digit Range At CER

23.10.2025 г., 05:05 ч. UTC

Печалби

Roche Expects An Increase In Group Sales In Mid-Single-Digit Range At CER

23.10.2025 г., 05:04 ч. UTC

Печалби

Roche: Group Sales Up 7% At Constant Exchange Rates In First Nine Months

23.10.2025 г., 05:02 ч. UTC

Печалби

Roche Had Seen High-Single-Digit 2025 Core Earnings Per Share Growth at CER

23.10.2025 г., 05:02 ч. UTC

Печалби

Roche Had Seen Mid-Single-Digit 2025 Sales Growth At Constant Exchange Rates

23.10.2025 г., 05:02 ч. UTC

Печалби

Roche 9-Mos CH45.9B

23.10.2025 г., 05:01 ч. UTC

Печалби

Roche Raises 2025 View

1.10.2025 г., 20:33 ч. UTC

Придобивния, сливания и поглъщания

Roche Begins Tender Offer for 89bio Pursuant to Previously Announced Merger Agreement

1.10.2025 г., 09:05 ч. UTC

Горещи акции

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

18.09.2025 г., 14:12 ч. UTC

Придобивния, сливания и поглъщания

89bio Stock Soars 86%. Why Roche Is Buying the Biopharma Company for $3.5 Billion. -- Barrons.com

18.09.2025 г., 07:37 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Roche's 89bio Acquisition Gives Its Drug Pipeline Potential Blockbuster -- Market Talk

18.09.2025 г., 05:09 ч. UTC

Придобивния, сливания и поглъщания

89bio Says Deal Reflects Potential of Pegozafermin Drug Candidate

18.09.2025 г., 05:06 ч. UTC

Придобивния, сливания и поглъщания

Roche: Deal Is Expected to Close in 4Q

18.09.2025 г., 05:06 ч. UTC

Придобивния, сливания и поглъщания

Roche: Deal Enhanc Portfolio in Cardiovascular, Renal, Metabolic Diseases

18.09.2025 г., 05:05 ч. UTC

Придобивния, сливания и поглъщания

Roche: MASH Is One of Most Prevalent Comorbidities of Obesity

18.09.2025 г., 05:05 ч. UTC

Придобивния, сливания и поглъщания

Roche: 89bio Developing Potential Treatment for Metabolic Dysfunction-Associated Steatohepatitis

18.09.2025 г., 05:04 ч. UTC

Придобивния, сливания и поглъщания

Roche to Buy 89bio for $14.50 a Share in Cash, Contingent Value Right of Up to $6 a Share

18.09.2025 г., 05:03 ч. UTC

Придобивния, сливания и поглъщания

Roche: Total Deal Value Is Up to $3.5B

Roche Holding AG Прогноза

Настроение

By Acuity

64 / 371 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
help-icon Live chat